MHRA approves first UK treatment for Friedreich’s ataxia, omaveloxolone

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 April, approved omaveloxolone (Skyclarys), the first treatment for patients aged 16 and over, in the UK for a rare neurodegenerative movement disorder called Friedreich’s ataxia.

MHRA approves first UK treatment for Friedreich’s ataxia, omaveloxolone